| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/01/2000 | EP0982401A2 Drug targets in Candida albicans |
| 03/01/2000 | EP0982397A1 Inhibition of contact system activation |
| 03/01/2000 | EP0982317A1 Bivalent inhibitors of the proteasome |
| 03/01/2000 | EP0982037A1 Preventives and/or remedies for sepsis |
| 03/01/2000 | EP0982036A1 Modulation of Beta2 -integrin-mediated cell adhesion |
| 03/01/2000 | EP0982035A1 Cyclosporin composition comprising an hydrophilic carrier |
| 03/01/2000 | EP0982027A1 Taxoid derivatives for treating abnormal cell proliferation of the brain |
| 03/01/2000 | EP0981649A1 Peptides which enhance transport of an active agent across tissues and compositions and methods of using the same |
| 03/01/2000 | EP0981642A1 Kappa b kinase, subunits thereof, and methods of using same |
| 03/01/2000 | EP0981632A2 Carbohydrate-deficient glycoprotein syndrome type i |
| 03/01/2000 | EP0981624A2 $i(LEISHMANIA) ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS |
| 03/01/2000 | EP0981620A1 Hgf polypeptides and their use in therapy |
| 03/01/2000 | EP0981618A1 Apo-2 RECEPTOR |
| 03/01/2000 | EP0981617A1 Recombinant lactoferrin, methods of production from plants and uses |
| 03/01/2000 | EP0981616A1 Ligand polypeptide for the g protein-coupled receptor from human pituitary glands |
| 03/01/2000 | EP0981615A1 Protein kinase c inhibitor-like protein (ipkc-2) |
| 03/01/2000 | EP0981613A1 PARG, A GTPase ACTIVATING PROTEIN WHICH INTERACTS WITH PTPL1 |
| 03/01/2000 | EP0981612A2 Secreted proteins and polynucleotides encoding them |
| 03/01/2000 | EP0981607A1 Modiified arginine deiminase |
| 03/01/2000 | EP0981606A2 Method and construct for inhibition of cell migration |
| 03/01/2000 | EP0981603A1 Models for haematopoiesis |
| 03/01/2000 | EP0981550A1 Methods for eosinophil depletion and compositions therefor |
| 03/01/2000 | EP0981549A1 A method for the improvement of neuronal regeneration |
| 03/01/2000 | EP0981547A1 Tumor-associated antigen |
| 03/01/2000 | EP0981545A1 Treatment of osteoporosis |
| 03/01/2000 | EP0981542A1 20(s) camptothecin glycoconjugates |
| 03/01/2000 | EP0981541A1 Psca: prostate stem cell antigen |
| 03/01/2000 | EP0981540A1 A NOVEL STRAIN OF $i(BACILLUS) FOR CONTROLLING PLANT DISEASES AND CORN ROOTWORM |
| 03/01/2000 | EP0981539A1 Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the c-terminus |
| 03/01/2000 | EP0981536A1 Fas ligand compositions for treatment of proliferative disorders |
| 03/01/2000 | EP0981521A2 Novel macrocyclic compounds as metalloprotease inhibitors |
| 03/01/2000 | EP0981511A1 Methods and compositions for the selective modification of nucleic acids |
| 03/01/2000 | EP0981377A1 Immobilized activity stabilized lhrh antagonist complexes, method for the production thereof |
| 03/01/2000 | EP0981375A1 Pharmaceutical compositions containing plasma protein |
| 03/01/2000 | EP0981374A2 Sustained-release delayed gels |
| 03/01/2000 | EP0981369A2 Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors |
| 03/01/2000 | EP0981365A1 Leptin as an inhibitor of tumor cell proliferation |
| 03/01/2000 | EP0981364A1 Method and compositions for treating hyperlipidemia and other conditions |
| 03/01/2000 | EP0981363A1 Somatostatin and somatostatin agonists for decreasing body weight |
| 03/01/2000 | EP0981362A1 Methods of enhancing functioning of the upper gastrointestinal tract |
| 03/01/2000 | EP0981361A1 Method of treating sepsis |
| 03/01/2000 | EP0981360A1 Method for preventing gastritis using amylin or amylin agonists |
| 03/01/2000 | EP0981359A1 Compositions for enhancing immunosuppressants' pharmaceutical activities |
| 03/01/2000 | EP0981358A1 Dolastatin-15 derivatives in combination with taxanes |
| 03/01/2000 | EP0981357A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 03/01/2000 | EP0981353A1 Facilitation of repair of neural injury with cm101/gbs toxin |
| 03/01/2000 | EP0981352A1 Aplidine as an l-type calcium channel enhancer |
| 03/01/2000 | EP0981332A1 Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation |
| 03/01/2000 | EP0981329A1 Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride |
| 03/01/2000 | EP0981282A1 Process for preparing a nutritional supplement |
| 03/01/2000 | EP0857063A4 Compositions and methods for buccal delivery of pharmaceutical agents |
| 03/01/2000 | EP0821592A4 Compositions and methods for regulating hair growth |
| 03/01/2000 | EP0770091B1 Compounds for reversing drug resistance |
| 03/01/2000 | EP0769020B1 NEW hIL-4 MUTANT PROTEINS USED AS ANTAGONISTS OR PARTIAL AGONISTS OF HUMAN INTERLEUKIN 4 |
| 03/01/2000 | EP0744949A4 Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration |
| 03/01/2000 | EP0618926B1 New peptide derivatives |
| 03/01/2000 | CN1246154A OB fusion protein compositions and methods |
| 03/01/2000 | CN1246151A Mutants of streptococcal toxin A and methods of use |
| 03/01/2000 | CN1246126A Antimicrobially active polypeptides |
| 03/01/2000 | CN1246125A Peptides comprising a T-cell epitope specific to collagen II |
| 03/01/2000 | CN1246069A A stabilized mixture comprising fibrinogen |
| 03/01/2000 | CN1246058A Oil-free pharmaceutical compositions containing cyclosporin A |
| 03/01/2000 | CN1246057A Oral cyclosporin formulations |
| 03/01/2000 | CN1245721A Method for preparing intestinal transmitted non-A and non-B hepatitis vaccine |
| 03/01/2000 | CN1245720A Medicinal composition containing calcineurin B subunit |
| 03/01/2000 | CN1245719A Antithrombosis medicine using inactive insuline as skeleton and containing arginine-glycine-aspartic acid sequence |
| 03/01/2000 | CN1049822C Application of epidermal growth factor in preparing medicine for curing atrophic gastritis |
| 03/01/2000 | CA2246791A1 Treatment of endothelium with somatostatin analogues |
| 02/29/2000 | US6031150 Genome with homozygous disruption of gene by selectable marker; for studying non-insulin dependent diabetes mellitus and persistent hyperinsulinemic hypoglycemia of infancy |
| 02/29/2000 | US6031112 Process for the production of alkoxycarbonyl-dipeptides intermediates in the synthesis of the lisinopril |
| 02/29/2000 | US6031090 Molecular cloning of a 7TM receptor (GPR31A) |
| 02/29/2000 | US6031081 Process for reactivating purified membrane proteins by freezing them |
| 02/29/2000 | US6031080 Chemotactic cytokine |
| 02/29/2000 | US6031077 For prevention and treatment of heartworm infections; parasiticides; anthelmintics |
| 02/29/2000 | US6031076 Conservin compositions |
| 02/29/2000 | US6031073 Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
| 02/29/2000 | US6031072 Compounds and methods for modulating cell adhesion |
| 02/29/2000 | US6031071 Oligopeptide of a generic amino acid sequence having a tryptophan or phenylalanine at a specific site; capable of binding molecules or their natural receptor; for agonists or antagonists |
| 02/29/2000 | US6031003 Calcium receptor-active molecules |
| 02/29/2000 | US6030972 2- or 5-aminomethyl,2- or 5-cyanopyrimidines as intermediates of anticoagulants in extracorporeal circulation (heart-lung machine, hemodialysis) |
| 02/29/2000 | US6030956 Vector to kill cancer cells in a variety of human malignancies |
| 02/29/2000 | US6030950 Pharmaceutical therapeutic use of glutathione derivative |
| 02/29/2000 | US6030949 Macrophage stimulating protein for the treatment of pathologies of the nervous system |
| 02/29/2000 | US6030948 Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
| 02/29/2000 | US6030947 Treating p150,95-mediated inflammation which comprises administering an anti-inflammatory agent comprising alpha-subunit of human p150,95 in association with beta-subunit of member of lfa-1 family of receptor molecules |
| 02/29/2000 | US6030946 Reversible cysteine protease inhibitors |
| 02/29/2000 | US6030945 Apo-2 ligand |
| 02/29/2000 | US6030944 Cyclohexapeptidyl bisamine compounds |
| 02/29/2000 | US6030943 Dehydrodidemnin B as an L-type calcium channel enhancer |
| 02/29/2000 | US6030942 Peptides peptide analogs peptidomimetics and other small molecules useful for inhibiting the activity of ribonucleotide reductase |
| 02/29/2000 | US6030940 Peptide analog inhibitors of urokinase receptor activity |
| 02/29/2000 | US6030837 Antisense inhibition of PEPCK-mitochondrial expression |
| 02/29/2000 | US6030834 Cdna (complementary dna) of human i kappa b kinase involved in activating transcription factors and causing inflammation; for drug screening of antiinflammatory agents |
| 02/29/2000 | US6030832 Dna sequence of protein which interacts with domain of tumor suppressor protein |
| 02/29/2000 | US6030831 Tie ligand homologues |
| 02/29/2000 | US6030830 Nucleotide sequences which are bridging templates for recombination of genomic dna resulting in immunoglobulin isotype switching; for treatment of allergies |
| 02/29/2000 | US6030826 Human parvulin-like protein |
| 02/29/2000 | US6030825 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 02/29/2000 | US6030822 Amino acid sequence; for treating skeletal muscle diseases, alzheimer's disease, or peripheral neuropathies in a mammal with an agonist or antagonist of kinase activity; antidiabetic agents |
| 02/29/2000 | US6030812 Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors |